Dr. Alison Egan Spellman, MD

Dr. Spellman practices at Candler Hospital in Savannah, Georgia, part of Sisters of Mercy.

Dr. Spellman's NPI, 1629393970, was assigned on March 30, 2010. Dr. Spellman graduated from Medical College of Georgia School of Medicine in 2010. Dr. Spellman holds Georgia license 070092.

Dr. Spellman's primary practice is Candler Hospital, at 5353 Reynolds Street, Savannah, GA 31405 in Chatham County. The practice phone is (912) 819-5290.

Dr. Spellman's primary practice is Candler Hospital in Savannah, Georgia, part of Sisters of Mercy. Dr. Spellman is also affiliated with Memorial Health University Medical Center. The medical group on file is Summit Cancer Care. Dmand AI also links Dr. Spellman to 2 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Spellman practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Spellman's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Spellman is licensed in Georgia.

CMS data shows 1,385 Medicare services from Dr. Spellman across 13 procedure codes in 2024, for 475 Medicare patients. Medicare paid $110,230 for them.

CMS counts 475 Medicare patients who saw Dr. Spellman in 2024. The largest group is 65 to 74, with 233 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.88, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Spellman's median patient age at 69, with 73% women.

In 2024, Dr. Spellman wrote 1,332 Medicare Part D claims for 287 patients. 83% of them were for generic drugs. CMS names the drug for 978 of them, across 29 drugs with 11 or more claims each, at $1,316,999 in total drug cost. In 2023, CMS named 1,255 claims across 35 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Spellman for performance year 2024, reported individually. Dr. Spellman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Spellman as offering telehealth.

Dmand AI links 1 paper to Dr. Spellman.

Dmand AI links Dr. Spellman to 5 clinical trials, 2 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Brain Neoplasms. Alliance for Clinical Trials in Oncology sponsors the most, 2.

CMS Open Payments shows 767 general payments to Dr. Spellman from 71 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. Novartis Pharmaceuticals Corporation paid the most, $1,333.

Dr. Spellman graduated from Medical College of Georgia School of Medicine in 2010.